What is the story about?
What's Happening?
Boston Scientific is developing a new version of its Watchman device, as announced during a recent investor presentation. Angelo De Rosa, the global president of Boston Scientific’s Watchman business, highlighted that the new device aims to offer improved adaptability to various anatomical structures. The Watchman device is designed to reduce stroke risk in patients with atrial fibrillation by sealing the left atrial appendage, a common source of blood clots. The company plans to start enrollment for a U.S. investigational device exemption study next year, with a potential launch in late 2027 or early 2028. The market for the Watchman device is projected to grow by 20% annually, with current indications for patients who can tolerate short-term but not long-term blood thinners.
Why It's Important?
The development of a new Watchman device by Boston Scientific is significant for the medical community and patients with atrial fibrillation. The device offers an alternative to long-term anticoagulant therapy, which can have adverse effects. By expanding the indications for the Watchman device, Boston Scientific aims to reach a broader patient population, potentially increasing the number of patients benefiting from this technology from 5 million to over 20 million by 2030. This expansion could lead to a substantial impact on healthcare costs and patient outcomes, as the device provides a less invasive option for stroke prevention.
What's Next?
Boston Scientific is conducting the Champion-AF study to compare the Watchman implant with blood thinners over five years, with results expected in the first half of 2026. Positive outcomes from this study, along with updates in reimbursement and guidelines, could significantly expand the device's market. The company is also working on integrating the Watchman device with ablation procedures for atrial fibrillation, which could further enhance its adoption and insurance coverage.
AI Generated Content
Do you find this article useful?
